Hurricane Helene's devastating impact on a major IV fluid supplier, Baxter's North Cove facility in North Carolina, is causing ongoing supply chain disruptions for hospitals across the U.S. While the facility has restarted operations, a significant shortage of intravenous solutions persists, affecting patient care.
The facility, which previously supplied approximately 60% of the nation's IV fluids, is gradually returning to full production. Eight of ten manufacturing lines have restarted, representing roughly 85% of pre-hurricane capacity. Baxter projects full production levels to be reached early in Q1 2025, though distribution channels require additional time.
Hospitals are responding to the shortage by conserving fluids, adjusting surgical schedules, and employing alternative hydration methods. The impact varies depending on individual hospital's reliance on Baxter as a supplier, their patient population, and fluid conservation strategies.
"Hospitals are receiving less than their normal required amounts," said Nancy Foster, vice president of quality and safety policy at the American Hospital Association (AHA). The current situation differs from previous shortages due to the FDA and the Administration for Strategic Preparedness and Response acting swiftly to expedite Baxter's recovery.
Despite progress, some hospitals anticipate the shortage continuing into January. Baxter and the FDA are working diligently to ensure the safety and quality of the fluids. Hospitals are expected to continue seeing improvements as more production lines come online and the FDA verifies product safety.
